Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Adenosine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 known ✓ | P47900 | 9/20 | 0.83 |
| ▸ | P2RY2 known ✓ | P41231 | 3/20 | 0.83 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.83 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.83 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.83 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.83 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.83 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.83 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.83 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.83 |
| ▸ | LDHA | P00338 | 1/20 | 0.83 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.83 |
| ▸ | FBP1 | P09467 | 1/20 | 0.83 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.83 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Phosphate SCHEMBL353218 | 1.00 | P2RY1 (0.83) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL145417 | 1.00 | P2RY1 (0.83) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL29364783 | 1.00 | P2RY1 (0.83) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL5600449 | 0.99 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL1164224 | 0.99 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL23093554 | 0.99 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL7064977 | 0.99 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL9068130 | 0.99 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL1164292 | 0.99 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL5434021 | 0.99 | P2RY1 (0.81) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075514-A | Use of glycogen phosphatase B agonists for the treatment of neurodegenerative diseases | — | 2026-05-26 | — | — | CN | claimed |
| CN-117551344-B | Low-moisture-absorption nylon material and preparation method thereof | 苏州优利金新材料有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117551344-A | Low-moisture-absorption nylon material and preparation method thereof | 苏州优利金新材料有限公司 | 2024-02-13 | — | — | CN | claimed |
| WO-2023234116-A1 | SKIN TREATMENT DEVICE, OPERATION METHOD FOR OPERATING SKIN TREATMENT DEVICE, SKIN TREATMENT METHOD AND PROGRAM | ヤーマン株式会社 | 2023-12-07 | — | — | WO | claimed |
| CN-109928999-B | Boron-containing compound, pharmaceutical composition, and preparation method and application of boron-containing compound | 童永彭 | 2020-11-06 | — | — | CN | claimed |
| US-20200215088-A1 | PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY | KNELLER BRUCE W (US) | 2020-07-09 | — | — | US | claimed |
| US-10624915-B2 | Palatinose for enhancing dietary supplement and pharmaceutical delivery | KNELLER BRUCE W (US) | 2020-04-21 | — | — | US | claimed |
| US-20170340657-A1 | PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY | KNELLER BRUCE W (US) | 2017-11-30 | — | — | US | claimed |
| US-8283327-B2 | Palatinose for enhancing dietary supplement and pharmaceutical delivery | KNELLER BRUCE W (US) | 2012-10-09 | — | — | US | claimed |
| US-20060153899-A1 | Palatinose for enhancing dietary supplement and pharmaceutical delivery | KNELLER BRUCE W | 2006-07-13 | — | — | US | claimed |
| US-4067775-A | Process and composition for determining the activity of creatinekinase-MB | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1978-01-10 | — | — | US | claimed |
| CN-122075514-A | Use of glycogen phosphatase B agonists for the treatment of neurodegenerative diseases | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260027034-A1 | COSMETIC COMPOSITION CONTAINING MICRONEEDLES OF POLYMER | JNTL CONSUMER HEALTH KK (JP) | 2026-01-29 | — | — | US | disclosed |
| EP-3389595-B1 | COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC ACID HAVING TWO OR MORE ACID DISSOCIATION CONSTANTS | OREAL (FR) | 2025-11-05 | — | — | EP | disclosed |
| EP-4608369-A1 | COSMETIC COMPOSITION CONTAINING MICRONEEDLES OF POLYMER | JNTL Consumer Health Kabushiki Kaisha (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-5017564-A | Vitamin B1 deravitive and disodium ATP | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0348688-A1 | Solid pharmaceutical preparation and method of producing same | Senju Pharmaceutical Co., Ltd. (JP) | 1990-01-03 | — | — | EP | disclosed |
| EP-0344795-A1 | Stabilized pharmaceutical composition and method of producing same | Senju Pharmaceutical Co., Ltd. (JP) | 1989-12-06 | — | — | EP | disclosed |
| US-4118279-A | OXYPOLYGELATINE | BOEHRINGER MANNHEIM GMBH (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4067775-A | Process and composition for determining the activity of creatinekinase-MB | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027034-A1 | COSMETIC COMPOSITION CONTAINING MICRONEEDLES OF POLYMER | CD44, CUTA, H1-0 | P2RY1 2310/4885P2RY2 2574/4885ADORA1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.